Yamanaka's iPSC Experiments Explained
In 2006, Shinya Yamanaka achieved something many biologists thought impossible: he and his postdoctoral researcher Kazutoshi Takahashi took specialized connective-tissue cells (fibroblasts) with a fixed identity and reprogrammed them back to a state of broad developmental potential. By introducing just four genes into mouse fibroblasts, they converted them into induced pluripotent stem cells (iPSCs), cells that could give rise to tissues from all three germ layers. The experiment showed that cell identity is not permanently locked in but can be reset. The discovery, published in August 2006 in Cell, earned him the 2012 Nobel Prize in Physiology or Medicine — shared with John Gurdon, whose frog nuclear transfer work in the 1960s had hinted at similar possibilities decades earlier.
The problem Yamanaka was trying to solve
For most of the 20th century, biologists assumed a one-way ratchet: development proceeded from stem cell to specialized cell, and that specialization was irreversible. A heart cell would always be a heart cell; a neuron would always be a neuron. Specialized cells had turned off their other genes permanently, and no known process could turn them back on.
The only route to pluripotency — the capacity to become any cell type — was through embryonic stem cells (ESCs), harvested from early embryos. These were invaluable for research but ethically contentious, and they could not be derived from a patient, ruling out their use in personalized medicine.
Pluripotency — the capacity of a cell to differentiate into any of the cell types that comprise the body, maintaining the ability to self-renew indefinitely. Pluripotent cells are foundational to both normal development and regenerative medicine applications.
Yamanaka's goal was to find a way to reprogram adult cells — which are abundant and uncontroversial — into a pluripotent state without destroying them or extracting them from embryos.
The experimental approach: screening transcription factors
Yamanaka started with a list of genes known to be active in embryonic stem cells but inactive in differentiated cells. He reasoned that reactivating those genes in adult cells might recreate the pluripotent state. His approach was to systematically test which of these genes, alone or in combination, could reprogram a fibroblast (a type of skin cell) back to pluripotency.
He began with 24 candidate genes, all encoding transcription factors — proteins that regulate which other genes are turned on or off. Over many months, he narrowed the list by testing combinations. Which genes, in which numbers, in which order, could flip a differentiated cell back to a stem cell state?
The breakthrough: four magic factors
From the 24 candidates, the team identified a minimal set: just four genes could do the job. The four genes were:
- Oct3/4 — a transcription factor critical for pluripotency
- Sox2 — another pluripotency factor
- Klf4 — a zinc-finger transcription factor
- c-Myc — an oncogene (cancer-promoting gene) that boosts cellular proliferation
When Yamanaka introduced these four genes into mouse fibroblasts using a retroviral vector (a modified virus used to deliver genes), a small fraction of the cells transformed. They lost their fibroblast appearance, formed colonies resembling embryonic stem cell colonies, and expressed embryonic stem cell marker genes. In many key tests the reprogrammed cells resembled embryonic stem cells, although, as described below, the 2006 cells were not yet a perfect match.
| Gene | Role |
|---|---|
| Oct3/4 | Transcription factor central to the pluripotent state |
| Sox2 | Transcription factor that works together with Oct3/4 |
| Klf4 | Zinc-finger transcription factor |
| c-Myc | Oncogene that promotes cell proliferation |
Together, the four Yamanaka factors help switch on the gene network that maintains pluripotency.
Inside the 2006 experiment: how the screen actually worked
The original paper, by Kazutoshi Takahashi and Shinya Yamanaka at Kyoto University, appeared in Cell in August 2006 under the title "Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors." Takahashi, then a postdoctoral researcher in Yamanaka's lab, did most of the bench work. The design is worth looking at closely, because its cleverness lay less in the genes than in the way the team could tell whether anything had worked.
The 24 candidates
The 24 candidate factors were not chosen at random. They were genes implicated in maintaining embryonic stem cells or in growth and tumor behavior, and they included Nanog, Oct3/4, Sox2, Klf4, c-Myc and Stat3. Several came out of the lab's own earlier database work on "ES cell-associated transcripts," genes enriched in embryonic stem cells.
The Fbx15 reporter trick
To detect rare successes among millions of cells, the team needed a readout that only pluripotent cells would pass. They used mice in which a βgeo cassette — a fusion of the β-galactosidase gene and a neomycin-resistance gene — had been knocked into the Fbx15 locus. Fbx15 is switched on in embryonic stem cells but silent in fibroblasts. Embryonic stem cells carrying two copies of the insert survived very high concentrations of the antibiotic G418, while somatic cells from the same mice died. Any fibroblast that survived G418 after receiving candidate genes had, by definition, reactivated at least part of the embryonic program.
Subtracting one factor at a time
No single factor among the 24 produced G418-resistant colonies. When all 24 were delivered together by retroviruses, the team obtained 22 resistant colonies. They then removed one factor at a time from the pool and watched which removals made colonies disappear. Ten candidates seemed important; further subtraction narrowed this to four: Oct3/4, Sox2, c-Myc and Klf4. The four-factor combination produced the most embryonic-stem-cell-like cells. This "leave-one-out" strategy turned an impossibly large search — the number of possible combinations of 24 genes runs into the millions — into a tractable experiment.
Testing the result
The team checked the resulting cells against embryonic stem cells on several fronts. The induced cells grew in ES-like colonies, expressed ES marker genes, and when injected under the skin of nude mice formed teratomas — benign tumors containing tissues from all three germ layers (for example, neural tissue, cartilage and gut-like epithelium). Injected into blastocysts, they contributed to the development of mouse embryos. That was strong evidence of pluripotency, but not the strongest: the 2006 cells did not produce live adult chimeras, and their gene expression and DNA methylation patterns were not identical to those of true ES cells. In the paper's own terms they were a promising but incomplete version of pluripotency.
The 2007 follow-ups: closing the gap
Within a year, three groups — Yamanaka's (Okita and colleagues), Rudolf Jaenisch's at the Whitehead Institute, and Konrad Hochedlinger's at Harvard — published papers in mid-2007 showing that a stricter selection produced much better cells. Yamanaka's team swapped the Fbx15 reporter for one driven by Nanog, a gene more tightly tied to true pluripotency. Nanog-selected iPS cells had gene expression and DNA methylation patterns closer to ES cells, and the four viral transgenes were strongly silenced in them.
Crucially, Okita's Nanog-selected cells produced adult chimeric mice, and the cells passed through the germ line to the next generation. That was the gold-standard test: the reprogrammed cells could make eggs or sperm. But the work also carried a warning, because a substantial fraction of the chimeras developed tumors that were linked to reactivation of the c-Myc transgene, and later work focused on reprogramming without it.
Human cells, two labs, two recipes
In November 2007, two teams reported human iPS cells almost simultaneously. Takahashi, Yamanaka and colleagues published in Cell using the same four factors (OCT3/4, SOX2, KLF4, c-MYC) on adult human dermal fibroblasts. James Thomson's group at the University of Wisconsin, led by Junying Yu, published in Science using a different set: OCT4, SOX2, NANOG and LIN28. Thomson's team noted that c-Myc expression could cause death and differentiation of human ES cells, which motivated a recipe without it. The fact that two independent labs, using partly different genes, reached the same endpoint was strong confirmation that reprogramming was real and robust. It also showed that the "Yamanaka factors" were one solution, not the only one.
Efficiency and the mystery of reprogramming
One striking aspect of the experiment was how inefficient it was. When Yamanaka introduced the four genes into a dish of millions of fibroblasts, only a small fraction of cells actually reprogrammed, on the order of 0.01 to 0.1 percent in early experiments. The reason remains incompletely understood. The genes were present in all cells, yet only a tiny fraction responded. This suggested that reprogramming requires not just the right genes but also rare stochastic (random) events — perhaps the right confluence of cellular state, timing, and epigenetic landscape.
This inefficiency, paradoxically, was proof of concept. It showed the reprogramming was genuine, not a trick of the technique. If the four genes could force all cells to transform, skeptics would argue they were merely selecting a pre-existing stem cell population hiding in the culture. But the low efficiency suggested that most cells resist the signal, and only those experiencing a rare permissive state can successfully reprogram.
Human iPSCs and clinical potential
Yamanaka's 2006 work used mouse cells. The key question for medicine was: would it work in humans? Within about a year, Yamanaka's group and Thomson's group adapted the protocol to human cells (see above). Human skin fibroblasts could be reprogrammed into pluripotent cells at low efficiency, and later work extended the approach to other cell types, including blood cells.
This achievement had profound implications. For the first time, researchers could generate pluripotent stem cells from a patient's own adult cells. Those cells could then be coaxed to differentiate into whatever cell type was needed — heart tissue for a failing heart, neurons for spinal cord injury, pancreatic beta cells for diabetes. Because the cells were genetically identical to the patient's original cells, transplanting them back would avoid immune rejection, a major barrier to cell transplantation therapy.
Why this mattered: reversing the dogma of irreversibility
Yamanaka's work demonstrated that cellular differentiation is, in principle, reversible. The genes controlling pluripotency and specialized cell types exist in both cell types; it is not that specialized cells have lost these genes but that they have silenced them through epigenetic mechanisms. Reactivate the silencing pattern, and differentiation unwinds.
Gurdon's 1960s nuclear-transfer work had already shown that differentiated nuclei retain the full genome, but Yamanaka's result showed that reversal could be triggered by a handful of genes alone. A cell's fate looks less like a permanent commitment and more like a configuration that can be reset.
Limitations and challenges
Despite the breakthrough, serious obstacles remain for clinical use. First, efficiency remains problematic. Generating enough iPSCs from a patient requires many rounds of culture, increasing cost and time. Second, the protocol originally used c-Myc, an oncogene, which raises concerns about cancer risk. Subsequent research has shown that replacing c-Myc with other factors can reduce tumorigenic potential, but safety remains an active area of research.
Third, iPSCs derived from different patients show variable quality and reprogramming kinetics, suggesting that the original cell type and the individual patient's genetics influence the ease of reprogramming. Some adult cell types are far easier to reprogram than others.
Fourth, an iPSC-derived cell is not yet fully equivalent to a natural cell of that type. iPSC-derived neurons, for example, often fail to achieve the electrophysiological properties of primary neurons. Improving differentiation protocols and ensuring fidelity to the target cell type remains an active challenge.
Making the method safer
Much of the decade after 2006 went into removing the riskiest parts of the original recipe. In late 2007 (print issue January 2008), Nakagawa and colleagues in Yamanaka's lab reported in Nature Biotechnology that iPS cells could be made with only three factors, leaving out c-Myc — at lower efficiency, but without the oncogene. A second concern was the delivery vehicle itself: retroviruses integrate into the host genome and can disrupt genes or reactivate later. Researchers turned to methods that leave no permanent footprint, including non-integrating viruses, episomal plasmids, synthetic messenger RNA and protein delivery. Clinical-grade iPS work today generally relies on such integration-free approaches plus extensive genetic screening of each cell line before use.
A residual safety issue applies to any pluripotent cell product, iPS or embryonic: if even a small number of undifferentiated cells slip into a transplant, they can form teratomas. Clinical protocols therefore purify the differentiated cell type and test for leftover pluripotent cells.
From the dish to the clinic
The first transplant, 2014
On September 12, 2014, a Japanese woman in her seventies with a form of age-related macular degeneration became the first person to receive tissue derived from iPS cells. The team, led by ophthalmologist Masayo Takahashi of the RIKEN Center for Developmental Biology, took skin cells from the patient, reprogrammed them into iPS cells, and differentiated those into retinal pigment epithelium (RPE) — the layer of support cells that degenerates in the disease. A sheet roughly 1.3 by 3 millimeters was implanted beneath her retina in Kobe. The goal of this first study was safety, not a cure: to show that iPS-derived cells could be transplanted without forming tumors or being rejected.
The case also exposed a practical problem. Making a custom cell line for each patient took months and was extremely costly. A planned second patient was not treated after the team found genetic changes in that patient's iPS cells, illustrating why each line must be screened. Japan subsequently shifted toward banks of iPS lines from healthy donors with common immune types, so that cells can be prepared in advance and matched to many recipients.
Parkinson's disease
In 2018 Kyoto University began an investigator-initiated phase I/II trial, led by neurosurgeon Jun Takahashi, transplanting iPS-derived dopaminergic progenitor cells into the brains of people with Parkinson's disease. Results published in Nature in April 2025 covered seven patients: there were no serious adverse events and no abnormal cell growth, and among six patients evaluated for efficacy, four improved on the standard motor score measured off medication and five improved on medication. These are small numbers in an open-label study, so they are encouraging rather than conclusive. A cell product based on this work, developed with Sumitomo Pharma (raguneprocel, brand name Amchepry), received conditional, time-limited approval from Japan's health ministry in early 2026, widely reported as the world's first approval of an iPS-cell-based therapy. The seven-year conditional period requires the company to collect further safety and efficacy data before full approval.
The STAP contrast: what a failed "easier" method shows
Yamanaka's result was striking enough that a simpler shortcut seemed plausible to some. In January 2014, Nature published two papers led by Haruko Obokata of RIKEN claiming that mouse cells could become pluripotent simply by being bathed in mild acid — "stimulus-triggered acquisition of pluripotency," or STAP. Other labs could not reproduce the result, and problems were found with images in the papers. A RIKEN investigative committee found Obokata guilty of research misconduct in April 2014, and Nature retracted both papers on July 2, 2014. Co-author Yoshiki Sasai, a respected developmental biologist, died by suicide weeks later.
The contrast is instructive. Yamanaka's protocol was surprising, but it was specified precisely, used defined genes and selectable markers, and was reproduced by independent labs within months — including labs that changed the factors. STAP depended on claims that could not survive replication. Reproducibility, not novelty, is what separated a Nobel-winning finding from a retracted one.
Common misconceptions
- "iPS cells are just embryonic stem cells under another name." They are very similar and pass the same functional tests, but they come from adult cells, involve no embryo, and can carry an epigenetic memory of their tissue of origin.
- "Yamanaka found a way to make cells young again, so it reverses aging." Reprogramming does reset some age-associated marks in cultured cells, and partial reprogramming is an active research area, but no treatment based on it has been shown to reverse aging in people.
- "The four factors are magic switches." They are a starting push. Most cells that receive them do not reprogram, and the process involves weeks of gradual changes in gene activity and chromatin.
- "iPS therapies are widely available." As of 2026 the clinical record consists mostly of early-phase trials, plus the first conditional, time-limited approvals in Japan. Unregulated clinics selling "stem cell" treatments are a separate, and often risky, matter.
The broader impact: iPSCs in research and disease modeling
Even before clinical applications materialized, iPSCs transformed basic research. Scientists can now reprogram cells from patients carrying genetic mutations and then differentiate them into the diseased cell type in a dish. This allows studying disease mechanisms in human cells without needing to biopsy patients or work with animal models. Researchers have used iPSCs to model neurodegenerative diseases, cardiac diseases, and metabolic disorders, providing insights into mechanisms and enabling drug screens.
iPSCs have also enabled the study of human development at stages that are inaccessible in living embryos, allowing researchers to trace how pluripotent cells gradually lose pluripotency and acquire specialized identities.
The connection to Gurdon and the long road to reversibility
Yamanaka's work was not the first hint that specialization could be reversed. In 1962, John Gurdon had transplanted the nucleus of a differentiated tadpole intestinal cell into an enucleated frog egg, and the egg developed into a normal tadpole. That experiment proved that differentiated cell nuclei retain the full genome and could, in principle, support complete development. But Gurdon's nuclear transplantation required reconstructing an entire embryo in an egg, a feat few could replicate. The same nuclear-transfer logic later produced Dolly the sheep in 1996 (see how Dolly was cloned), which showed that adult mammalian nuclei could also be reset — though only inside an egg, whose unknown contents did the resetting.
Yamanaka's own path was unusual. He trained as an orthopedic surgeon before switching to research, did postdoctoral work at the Gladstone Institutes in San Francisco, and led an independent lab at the Nara Institute of Science and Technology before moving to Kyoto University. The question his team asked was in effect a reverse of Gurdon's: if the egg contains factors that reset a nucleus, could a handful of those factors be identified and delivered without an egg at all?
Yamanaka's achievement was to identify the minimal genetic change needed to achieve pluripotency without reconstructing an embryo. Where Gurdon showed it was theoretically possible, Yamanaka showed it was practically achievable and reproducible in mammalian cells. The two discoveries complemented each other, and the Nobel Prize recognized this — Yamanaka and Gurdon shared it in 2012.
The takeaway
Yamanaka's four-factor reprogramming proved that the relationship between genotype and phenotype — genes and cell type — is more flexible than decades of dogma suggested. A fully specialized adult cell can be reset to pluripotency by reactivating a small set of transcriptional regulators. This discovery opened new avenues for regenerative medicine, disease modeling, and basic research into the mechanisms controlling cell fate. Today, iPSCs are a cornerstone of stem cell biology, with thousands of labs worldwide using them to study development, disease, and potential therapeutics.
Sources
- ASU - Induced Pluripotent Stem Cell Experiments 2006-2007
- Takahashi, K. & Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 126(4), 663-676
- Nobel Prize - Shinya Yamanaka Lecture (2012)
- Japan grants world's first approval for iPS cell-based therapy to treat Parkinson's disease (GxP News, March 2026)
- Okita, Ichisaka & Yamanaka (2007) - Generation of germline-competent induced pluripotent stem cells, Nature (PubMed)
- Yu et al. (2007) - Induced pluripotent stem cell lines derived from human somatic cells, Science (PubMed)
- ASU Embryo Project - Generation of iPS cells without Myc (Nakagawa et al., 2007/2008)
- Asian Scientist - World's First iPS Transplant Performed (2014)
- CiRA Reporter - Kyoto University Parkinson's iPS trial
- RIKEN - Statement on the retraction of the STAP papers (July 2, 2014)
- Scientific American - Scientist Resigns as Stem-Cell Creation Method Is Discredited
FAQ
Q: Why did Yamanaka choose those specific four genes?
A: Yamanaka started with 24 genes known to be active in embryonic stem cells. Through systematic testing of combinations, the team found that these four were enough to reprogram mouse fibroblasts. The choice was empirical — they tested combinations and found this minimal set worked best. Later work showed that c-Myc can be omitted, at lower efficiency.
Q: How safe are iPSCs for medical use?
A: iPSCs carry some inherent risks, particularly if c-Myc is used in reprogramming (it's an oncogene). Modern protocols use safer alternatives, but thorough testing for tumorigenicity is standard before clinical use. The field is still developing safety protocols and standards.
Q: Why is reprogramming so inefficient?
A: The exact reason remains unclear, but it likely reflects the complexity of the genetic networks controlling cell fate. Most cells resist the reprogramming signal; only those in a rare permissive epigenetic state successfully reprogram. This inefficiency is actually evidence that reprogramming is a genuine biological process, not an artifact.
Q: Can iPSCs be made from any cell type?
A: Not easily. Blood cells and skin fibroblasts are the easiest to reprogram. Some cell types are far more resistant. Additionally, aging seems to reduce reprogramming efficiency — cells from older donors reprogram less readily than those from young donors.
Q: Are iPSCs the same as embryonic stem cells?
A: They are functionally similar but not identical. Both are pluripotent and can self-renew, but iPSCs often retain epigenetic "memory" of their original cell type, subtly affecting their behavior. They are extremely similar, but detailed comparisons reveal differences in gene expression patterns.
Q: Have iPSC therapies been approved by the FDA?
A: Not to our knowledge. Japan's health ministry granted conditional, time-limited approval in early 2026 to an iPS-cell-derived therapy for Parkinson's disease (Sumitomo Pharma's raguneprocel), but we found no FDA approval of an iPSC-derived therapy. Other iPSC-derived products, including retinal cells for macular degeneration, remain in clinical trials. Check current regulatory status before relying on this answer.
Read next:
Follow new articles
Add SciHub101 to your feed reader to see new science and technology stories.
About the Author
SciHub101 is an independent science and technology publication founded and edited by Buğra Sözeri, a software engineer and app developer based in Türkiye. AI tools assist with drafting and research. Source documentation in the existing archive is uneven, and articles are being reviewed and corrected. The Editorial Team byline identifies editorial responsibility; it does not certify specialist or independent human review. Where we compare products, anything built by our own team is labelled as such — see the editorial guidelines and About page for how corrections and disclosures work.
Related Articles

Organ Development in Microgravity: Growing Tissues Beyond Earth
ISS bioprinters and bioreactors are growing heart, retina, and cartilage tissue in orbit. Here's the real science behind space-based tissue engineering.

The Gurdon Frog Cloning Experiment: How a Tadpole Gut Cell Became a New Frog
John Gurdon transplanted intestinal nuclei into enucleated frog eggs in 1962, proving cell differentiation is reversible. His work led directly to Dolly the sheep and iPSCs.

Organoids Explained: What Mini-Organs Can and Cannot Model
Organoids are 3D cell cultures that self-organize into organ-like structures. See how they are grown, what they have taught us, and why they are not tiny organs.

The Science of Animal Regeneration: How Axolotls, Planarians, and Starfish Rebuild Themselves
An axolotl can regrow an amputated limb — including bones, nerves, blood vessels, muscle, and skin — in perfect working order within six weeks. It can also regrow portions of its brain, heart, and spinal cord. A planarian flatworm cut into 200 pieces will grow 200 new worms, each complete. The genetics behind these abilities are not alien to mammals; we have most of the same genes. The question is why we stopped using them.